Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

Bayer’s Eylea cleared for wider use in Europe

Macular oedema treatment reached €759m in sales last year

- PMLiVE

Sanofi joins WHO-backed diabetes mHealth programme

Becomessole pharma partner for Be Healthy, Be Mobile's diabetes arm

- PMLiVE

Russian innovation at the crossroads

Despite improvements, investors face rising risks

- PMLiVE

2015: A year of promise and connectivity

How could technology impact healthcare in this year and what will be the key trends to follow?

- PMLiVE

Mapping KOL relationships

Network maps can deliver a wealth of information

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

Sanofi reception

Sanofi gets green light for Lantus follow-up Toujeo

Once-daily basal insulin gains FDA approval for diabetes

- PMLiVE

Eisai adds online patient stories to Belviq marketing

Belviq Voices 'online community' will featureweight loss patient experiences

- PMLiVE

Actavis gets FDA nod for new antibiotic

Avycaz is the fifth antibiotic to gain US approval in recent months

Bristol-Myers Squibb (BMS) building

BMS buys immunotherapy specialist Flexus in $1.2bn deal

And signs new cancer research partnership with Rigel

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links